Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Radient Pharmaceuticals (RPC), in partnership with Jaiva Technologies, has formed a wholly owned subsidiary NuVax Therapeutics.
Subscribe to our email newsletter
NuVax, a clinical stage pharmaceutical company, aims to develop novel immune-gene therapeutics that have the potential to impact and extend the quality of life for cancer patients.
Through the newly formed NuVax Therapeutics, RPC and Jaiva Technologies will utilise RPC’s Combined Immunogene Therapy (CIT) cancer therapy to carry out human phase II clinical trials and develop products that will be first in-line therapies for largely unmet medical needs for cancer.
The rights to RPC’s CIT technology are anticipated to be transferred to NuVax and 100% of future product development and commercialisation, including the development and in-licensing of the up to five additional cancer-fighting technologies will be managed through NuVax.
RPC chairman and CEO Douglas MacLellan said the formation of NuVax Therapeutics provides a platform to accelerate and expand their planned collaboration with Jaiva Technologies, specifically as it relates to the commercialisation of CIT, in-licensing new cancer therapies and conducting stage II human clinical trials to ultimately introduce these products to market.